Dasiglucagon
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia, Type 1 Diabetes
Trial Timeline
May 9, 2023 → Dec 3, 2024
NCT ID
NCT05378672About Dasiglucagon
Dasiglucagon is a phase 3 stage product being developed by Novo Nordisk for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05378672. Target conditions include Hypoglycemia, Type 1 Diabetes.
What happened to similar drugs?
2 of 13 similar drugs in Hypoglycemia were approved
Approved (2) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05378672 | Phase 3 | Completed |
Competing Products
20 competing products in Hypoglycemia